Literature DB >> 32710825

Quantification of CpG Motifs in rAAV Genomes: Avoiding the Toll.

J Fraser Wright1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32710825      PMCID： PMC7403467          DOI： 10.1016/j.ymthe.2020.07.006

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  15 in total

Review 1.  A critical analysis of codon optimization in human therapeutics.

Authors:  Vincent P Mauro; Stephen A Chappell
Journal:  Trends Mol Med       Date:  2014-09-25       Impact factor: 11.951

2.  Structural basis of CpG and inhibitory DNA recognition by Toll-like receptor 9.

Authors:  Umeharu Ohto; Takuma Shibata; Hiromi Tanji; Hanako Ishida; Elena Krayukhina; Susumu Uchiyama; Kensuke Miyake; Toshiyuki Shimizu
Journal:  Nature       Date:  2015-02-09       Impact factor: 49.962

3.  CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells.

Authors:  G Hartmann; G J Weiner; A M Krieg
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

Review 4.  CpG DNA as a vaccine adjuvant.

Authors:  Christian Bode; Gan Zhao; Folkert Steinhagen; Takeshi Kinjo; Dennis M Klinman
Journal:  Expert Rev Vaccines       Date:  2011-04       Impact factor: 5.217

5.  Selectivity of Human TLR9 for Double CpG Motifs and Implications for the Recognition of Genomic DNA.

Authors:  Jelka Pohar; Chikako Yamamoto; Ryutaro Fukui; Miša-Mojca Cajnko; Kensuke Miyake; Roman Jerala; Mojca Benčina
Journal:  J Immunol       Date:  2017-01-23       Impact factor: 5.422

Review 6.  DNA methylation: an introduction to the biology and the disease-associated changes of a promising biomarker.

Authors:  Jörg Tost
Journal:  Mol Biotechnol       Date:  2010-01       Impact factor: 2.695

7.  Type I IFN Sensing by cDCs and CD4+ T Cell Help Are Both Requisite for Cross-Priming of AAV Capsid-Specific CD8+ T Cells.

Authors:  Jamie L Shirley; Geoffrey D Keeler; Alexandra Sherman; Irene Zolotukhin; David M Markusic; Brad E Hoffman; Laurence M Morel; Mark A Wallet; Cox Terhorst; Roland W Herzog
Journal:  Mol Ther       Date:  2019-11-15       Impact factor: 11.454

Review 8.  A cell biological view of Toll-like receptor function: regulation through compartmentalization.

Authors:  Gregory M Barton; Jonathan C Kagan
Journal:  Nat Rev Immunol       Date:  2009-06-26       Impact factor: 53.106

9.  Timing of Intensive Immunosuppression Impacts Risk of Transgene Antibodies after AAV Gene Therapy in Nonhuman Primates.

Authors:  Benjamin J Samelson-Jones; Jonathan D Finn; Patricia Favaro; J Fraser Wright; Valder R Arruda
Journal:  Mol Ther Methods Clin Dev       Date:  2020-05-12       Impact factor: 6.698

10.  Methylation Status of the Adeno-Associated Virus Type 2 (AAV2).

Authors:  Renáta Tóth; István Mészáros; Daniela Hüser; Barbara Forró; Szilvia Marton; Ferenc Olasz; Krisztián Bányai; Regine Heilbronn; Zoltán Zádori
Journal:  Viruses       Date:  2019-01-09       Impact factor: 5.048
View more
  9 in total

1.  Human and Insect Cell-Produced Recombinant Adeno-Associated Viruses Show Differences in Genome Heterogeneity.

Authors:  Ngoc Tam Tran; Emilie Lecomte; Sylvie Saleun; Suk Namkung; Cécile Robin; Kristina Weber; Eric Devine; Veronique Blouin; Oumeya Adjali; Eduard Ayuso; Guangping Gao; Magalie Penaud-Budloo; Phillip W L Tai
Journal:  Hum Gene Ther       Date:  2022-04       Impact factor: 4.793

2.  Coagulation factor IX gene transfer to non-human primates using engineered AAV3 capsid and hepatic optimized expression cassette.

Authors:  Sandeep R P Kumar; Jun Xie; Shilang Hu; Jihye Ko; Qifeng Huang; Harrison C Brown; Alok Srivastava; David M Markusic; Christopher B Doering; H Trent Spencer; Arun Srivastava; Guangping Gao; Roland W Herzog
Journal:  Mol Ther Methods Clin Dev       Date:  2021-08-26       Impact factor: 6.698

Review 3.  Adeno-Associated Viruses (AAV) and Host Immunity - A Race Between the Hare and the Hedgehog.

Authors:  Kleopatra Rapti; Dirk Grimm
Journal:  Front Immunol       Date:  2021-10-29       Impact factor: 7.561

Review 4.  Risk Mitigation of Immunogenicity: A Key to Personalized Retinal Gene Therapy.

Authors:  Juliette Varin; Clément Morival; Noémien Maillard; Oumeya Adjali; Therese Cronin
Journal:  Int J Mol Sci       Date:  2021-11-26       Impact factor: 5.923

Review 5.  Genome editing for primary immunodeficiencies: A therapeutic perspective on Wiskott-Aldrich syndrome.

Authors:  Asma Naseem; Zohar Steinberg; Alessia Cavazza
Journal:  Front Immunol       Date:  2022-08-18       Impact factor: 8.786

Review 6.  Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper.

Authors:  Tong-Yuan Yang; Manuela Braun; Wibke Lembke; Fraser McBlane; John Kamerud; Stephen DeWall; Edit Tarcsa; Xiaodong Fang; Lena Hofer; Uma Kavita; Vijay V Upreti; Swati Gupta; LiNa Loo; Alison J Johnson; Rakesh Kantilal Chandode; Kay-Gunnar Stubenrauch; Maya Vinzing; Cindy Q Xia; Vibha Jawa
Journal:  Mol Ther Methods Clin Dev       Date:  2022-08-02       Impact factor: 5.849

7.  Gene therapy - are we ready now?

Authors:  Radoslaw Kaczmarek
Journal:  Haemophilia       Date:  2022-05       Impact factor: 4.263

8.  Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood.

Authors:  Corinne J Smith; Nikki Ross; Ali Kamal; Kevin Y Kim; Elizabeth Kropf; Pascal Deschatelets; Cedric Francois; William J Quinn; Inderpal Singh; Anna Majowicz; Federico Mingozzi; Klaudia Kuranda
Journal:  Front Immunol       Date:  2022-09-16       Impact factor: 8.786

9.  Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy.

Authors:  Thais B Bertolini; Jamie L Shirley; Irene Zolotukhin; Xin Li; Tsuneyasu Kaisho; Weidong Xiao; Sandeep R P Kumar; Roland W Herzog
Journal:  Front Immunol       Date:  2021-05-31       Impact factor: 7.561
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.